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Mass Deworming Programs in Middle 
Childhood and Adolescence
Donald A. P. Bundy, Laura J. Appleby, Mark Bradley, 
Kevin Croke, T. Deirdre Hollingsworth, Rachel Pullan, 
Hugo C. Turner, and Nilanthi de Silva 
Chapter 13
INTRODUCTION
The current debate on deworming presents an interest-
ing public health paradox. Self-treatment for intestinal 
worm infection is among the most common self- 
administered public health interventions, and the deliv-
ery of donated drugs through mass drug administration 
(MDA) programs for soil-transmitted helminths (STHs) 
exceeds 1 billion doses annually. The clinical literature, 
especially the older historical work, shows significant 
impacts of intense STH infection on health; a burgeon-
ing economics literature shows the long-run conse-
quences for development (see, for example, chapter 29 in 
this volume, Ahuja and others 2017; Fitzpatrick and 
others 2017). Yet, the literature on clinical trials shows 
conflicting results, and the resulting controversy has 
been characterized as the worm wars.
The two previous editions of Disease Control Priorities 
contain chapters on STH and deworming programs 
(Hotez and others 2006; Warren and others 1993). Much 
of the biological and clinical understanding reflected in 
those chapters remains largely unchanged. This chapter 
presents current estimates of the numbers infected and 
the disease burden attributable to STH infections to illu-
minate current program efforts, advances in the under-
standing of epidemiology and program design, and the 
controversy regarding the measurement of impact. 
Definitions of age groupings and age-specific terminol-
ogy used in this volume can be found in chapter 1 
(Bundy, de Silva, and others 2017).
ESTIMATED NUMBER OF INFECTIONS AND 
DISEASE BURDEN
Three types of STH commonly infect humans: round-
worm (Ascaris lumbricoides), hookworm (comprising 
two species, Ancylostoma duodenale and Necator amer-
icanus), and whipworm (Trichuris trichiura). Recent 
use of geographic information systems and interpo-
lated climatic data have identified the distributional 
limits of STHs on the basis of temperature and rainfall 
patterns as well as socioeconomic factors (Pullan and 
Brooker 2012). Globally, in 2010 an estimated 5.3 
billion people, including 1 billion school-age children, 
lived in areas stable for transmission of at least one 
STH species; 69 percent of these individuals lived 
in Asia.
Map 13.1 is based on clear limiting relationships 
observed between infection and climatic factors for each 
species. For example, experimental and observational 
findings suggest that transmission is implausible in 
extremely hot, arid, or cold environments, particularly in 
Africa and the Middle East (Brooker, Clements, and 
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Bundy 2006; Brooker and Michael 2000; Pullan and 
Brooker 2012). Relationships are less clear in Asia, espe-
cially for roundworm, for which positive survey data 
exist even in extremely hot and arid regions of India and 
Pakistan, perhaps because resistant transmission stages 
allow for seasonal transmission in environments other-
wise hostile for much of the year.
Several attempts have been made to estimate world-
wide prevalence of STHs since the first estimates 
assembled by Norman Stoll in the seminal paper titled 
“This Wormy World” (Stoll 1947); this section pro-
vides revised estimates of the burden of disease for 
STHs in 2013. The number of persons infected with 
STHs is generated by applying the revised estimates 
from 2010 (Pullan and others 2014) to age-stratified 
population estimates for 2013. These estimates build 
on a modeling framework that exploits relationships 
between infection prevalence, intensity, and potential 
morbidity originally proposed by Chan and Bundy 
(1999) for use in the first Global Burden of Disease 
study (Chan 1997). In brief, the age-stratified mean 
prevalence was estimated for all endemic regions at 
subnational scales. The approach used to map the 
mean prevalence of infection within the boundaries of 
transmission differed by region, determined by the 
progress in control, environmental associations, and 
data availability considerations. For Asia, Latin 
America and the Caribbean, the Middle East and 
North Africa, and Oceania, empirical estimates were 
generated directly from the data. For countries within 
Sub-Saharan Africa—where detailed data were lack-
ing for several countries but where relationships 
between infection patterns and environmental factors 
were clearer—a geostatistical space-time modeling 
Map 13.1 Distribution of Soil-Transmitted Helminth Infection Risk, Applying Climatic Exclusion Limits
IBRD 42565  |  DECEMBER 2016
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Less stable transmission of at least one STH
Beyond transmission limits for all three species
GDP > US$20,000
Urban extent
Peri-urban extent
Source: Adapted from Pullan and Brooker 2012.
Note: Analysis includes only regions considered endemic for STHs. GDP = gross domestic product; STH = soil-transmitted helminth.
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framework was used to predict the prevalence of each 
infection across the continent, following the approach 
of Hay and others (2009).
For STHs, prevalence alone does not provide a 
useful measure of potential morbidity because only a 
small number of infections will be associated with ill 
health. Instead, morbidity is related to the intensity of 
infection, with the most intense infections occurring in 
only a minority of infected individuals (Bundy and 
Medley 1992). As prevalence increases, the prevalence 
of high-intensity infections increases at a higher rate, 
such that high-prevalence communities experience 
disproportionate amounts of morbidity (Chan and 
others 1994). Heterogeneity between communities 
within subnational areas was therefore approximated 
using modeled distributions, and the number of per-
sons with infection intensities greater than age- 
dependent thresholds was estimated indirectly for each 
species. The frequency distributions of worms, and 
thus the numbers exceeding these thresholds, were 
estimated using negative binomial distributions that 
assumed general species-specific aggregation parame-
ters based on data from Brazil, Kenya, and Uganda 
(Pullan and others 2014). The Institute for Health 
Metrics and Evaluation then used these estimates to 
estimate disability-adjusted life years (DALYs) for 2013 
(Murray and others 2015).
In 2013, an estimated 0.4 billion children under age 
15 years worldwide were infected with at least one spe-
cies of intestinal nematode, resulting in 1.46 million 
DALYs. Although the greatest number of DALYs occur in 
Sub-Saharan Africa and Latin America (map 13.2), a 
large at-risk population means that the vast majority of 
total infections occur in Asia, where at least one-fourth 
of preschool and school-age children are host to at least 
one STH species (table 13.1). The most important STH 
infection globally for children is roundworm, reflecting 
the age distribution of infection. Roundworm is of par-
ticular concern for preschool-age children in Sub-
Saharan Africa, resulting in 143 DALYs per 100,000 
population (table 13.2)—mostly attributable to wasting 
resulting from high-intensity infections. These figures 
are substantially lower than previous estimates (de Silva 
and others 2003), attributable in part to several method-
ological improvements:
• Limitation of populations at risk to areas suitable for 
transmission
• Increased availability of contributing survey data
• Generation of estimates at higher spatial resolutions.
Sources: IHME (Institute for Health Metrics and Evaluation). 2014. “Global Burden of Disease Study 2013: Age-Speciﬁ c All-Cause and Cause-Speciﬁ c Mortality 1990–2013.” 
IHME, Seattle, Washington.
Note: DALY = disability-adjusted life year. Soil-transmitted helminths include hookworm, roundworm, and whipworm.
Map 13.2 Distribution of DALYs for Soil-Transmitted Helminth Infections, per 100,000 Population
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Table 13.1 Total Population, Number of Infected Persons, and Overall Prevalence, 2015
Indicator
Total 
population 
(millions)
Number of Persons Infected (millions)
(95% CI)
Overall Prevalence
(95% CI)
Hookworm 
(millions)
Roundworm 
(millions)
Whipworm 
(millions)
Any STH 
(millions) Hookworm Roundworm Whipworm Any STH
Preschool age (younger than age five years)
Middle East and 
North Africa 
55.6 0.3
(0.2–0.3)
1.9
(1.2–2.8)
0.6 
(0.4–1.0)
2.5
(1.7–3.7)
0.5
(0.3–0.6)
3.4 
(2.2–4.9)
1.2
(0.8–1.7)
4.6
(3.1–6.6)
Latin America and 
the Caribbean 
54.5 1.7
(1.1–2.6)
5.3
(3.1–8.4)
4.6
(2.9–7.1)
10.1
(6.3–14.8)
3.2
(2.0–4.8)
9.7 
(5.7–15.4)
8.5
(5.3–13.0)
18.4
(11.6–27.2)
Sub-Saharan Africa 210.7 12.5
(7.7–19.1)
17.8
(10.6–27.8)
13.4
(7.7–21.5)
37.4
(23.1–55.3)
5.9
(3.7–9.1)
8.4 
(5.0–13.2)
6.4
(3.7–10.2)
17.7
(11.0–26.3)
East Asia and Pacific 151.0 14.6 
(8.9–22.6) 
13.4 
(7.0–22.5) 
12.5 
(6.8–20.2) 
34.1 
(20.2–51.6) 
9.6
(5.9–14.9)
8.8
(4.7–14.9)
8.1
(4.5–13.4)
22.6
(13.4–34.2)
South Asia 172.4 7.5 
(4.8–11.1) 
20.0
(11.8–30.6) 
6.8 
(4.0–11.0) 
30.0 
(18.4–43.6) 
4.4
(2.8–6.4)
11.6
(6.8–17.8)
4.0
(2.3–6.4)
17.3
(10.7–25.3)
Total 644.2 36.6
(22.7–55.7)
58.4
(33.9–93.0)
37.9
(21.7–60.8)
114.1
(70.0–170.0)
5.7
(3.5–8.7)
9.1 
(5.3–14.4)
5.9
(3.4–9.4)
17.8
(10.9–26.4)
School age (ages 5–14 years)
Middle East and 
North Africa 
94.4 0.7 
(0.4–0.9)
5.0
(3.4–7.2)
1.8
(1.2–2.6)
6.8
(4.6–9.6)
0.7
(0.5–1.0)
5.3 
(3.6–7.6)
1.9
(1.2–2.8)
7.2
(4.9–10.2)
Latin America and 
the Caribbean 
107.0 4.5
(2.9–6.8)
15.0
(9.4–22.6)
13.0
(8.5–19.2)
27.3
(18.1–38.4)
4.2
(2.7–6.3)
14.0
(8.8–21.1)
12.2
(7.9–17.9)
25.5
(16.9–35.9)
Sub-Saharan Africa 354.3 34.0
(21.6–50.4)
47.2
(30.0–70.1)
36.4
(22.2–55.5)
94.8
(62.7–131.0)
9.6
(6.1–14.2)
13.3 
(8.4–19.8)
10.3
(6.3–15.7)
26.7
(17.7–37.0)
East Asia and Pacific 294.0 44.3 
(27.8–63.2) 
34.2 
(18.5–55.8) 
32.0
(18.7–50.8)
88.0
(55.1–127.1) 
15.1
(9.4–21.5)
11.6
(6.3–19.0)
10.9
(6.4–17.3)
30.0
(18.7–43.2)
South Asia 343.0 24.7 
(16.3–35.4) 
63.0 
(39.1–91.5) 
21.7 
(12.8–33.7) 
90.5
(59.5–124.3) 
7.2
(4.7–10.3)
18.3
(11.4–26.7)
6.3
(3.7–9.8)
26.4
(17.3–36.2)
Total 1,192.8 108.2
(68.0–156.6)
164.4
(100.6–249.2)
105.0
(63.3–161.9)
307.4
(200.7–432.4)
8.9
(5.7–13.1)
13.9 
(8.4–20.9)
8.8
(5.3–13.6)
25.9
(16.8–36.2)
Source: Adapted from Pullan and others 2014.
Note: CI = conﬁ dence interval; STH = soil-transmitted helminth. Numbers in parentheses indicate range at 95 percent conﬁ dence interval.
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Table 13.2 DALYs per 100,000 Population, by Region and Type of Soil-Transmitted Helminth
DALYs per 100,000
Hookworm Roundworm Whipworm
Preschool age (younger than age 5 years) 
Middle East and North Africa 4.2 (2.4–6.4) 14.3 (9.9–19.7) 0.0 (0.0–0.1)
Latin America and the Caribbean 21.8 (13.1–34.1) 34.1 (24.6–46.1) 8.2 (4.3–15.2)
Sub-Saharan Africa 39.7 (25.3–59.7) 143.2 (117.6–173.7) 6.5 (3.7–10.6)
East Asia and Pacific 21.7 (13.4–34.2) 19.7 (13.3–28.9) 7.3 (3.3–14.0)
South Asia 19.3 (11.4–29.8) 43.1 (32.2–58.0) 2.0 (0.9–3.8)
School age (ages 5–14 years) 
Middle East and North Africa 7.3 (4.4–11.0) 4.8 (2.7–8.2) 0.1 (0.0–0.3)
Latin America and the Caribbean 73.7 (47.0–107.7) 19.2 (10.7–31.8) 16.9 (8.7–30.2)
Sub-Saharan Africa 80.7 (51.8–120.2) 33.7 (22.5–49.6) 18.1 (10.0–30.2)
East Asia and Pacific 52.7 (34.0–78.5) 11.6 (6.0–20.9) 14.4 (6.3–28.5)
South Asia 38.1 (22.8–58.4) 36.6 (21.4–60.6) 5.2 (2.5–9.5)
Source: Institute for Health Metrics and Evaluation, Global Health Data Exchange, http://ghdx.healthdata.org/.
Note: CI = conﬁ dence interval. Numbers in parentheses indicate range at 95 percent CI.
Results are still limited by the paucity of recent data, 
especially for much of Asia. These prevalence estimates 
were informed by a comprehensive review of population- 
based surveys conducted between 1980 and 2010. 
However, a number of coordinated efforts have been 
underway recently to scale up and complete the mapping 
for neglected tropical diseases (NTDs), including STHs. 
It will be important to ensure that future revisions of the 
Global Burden of Diseases, Injuries, and Risk Factors 
Study incorporate these new prevalence estimates when 
producing revised DALYs for STHs.
Map 13.3 shows the current distribution of STH 
infections. These infections were historically prevalent 
in many parts of the world where they are now 
uncommon. These areas include parts of Europe; 
Japan; the Republic of Korea; Taiwan, China; and the 
Caribbean and North America (Mexico and the United 
States), where sustained control efforts and economic 
development have led to their elimination, at least as a 
public health problem (Hong and others 2006; 
Kobayashi, Hara, and Kajima 2006; Tikasingh, Chadee, 
and Rawlins 2011). The distribution of worm species 
also reflects social and environmental factors, with 
greater transmission of hookworm infection in rural 
areas, and greater prevalence of roundworm and 
whipworm in periurban environments (Pullan and 
Brooker 2012).
The distribution of STH infection is declining, par-
tially as a result of global economic development, declin-
ing poverty, and greater access to health services and 
sanitation programs, especially in poor communities. It 
seems probable that the targeting of more than 1 billion 
deworming treatments a year in poor communities has 
also contributed. More contemporary surveys and 
joined-up databases are needed for reliable estimates, 
but crude estimates suggest that the number of school-
age children living with worm infection was cut in half 
from 2010 to 2015.
SCALE OF DEWORMING PROGRAMS
Deworming programs have long been popular with 
public health teams and the people exposed to infection. 
Norman Stoll’s “This Wormy World” provided a clear 
vision of the ubiquity of infection and the scale of 
deworming programs in the then-endemic areas, 
including the U.S. South (Stoll 1947). Since the begin-
ning of the twentieth century, schools have been viewed 
as the natural base for programs because they provide 
an existing infrastructure to reach the age group for 
whom infection is often most intense and who might 
benefit the most from deworming at a stage when they 
are still learning and growing (Bundy, Schultz, and 
others 2017, chapter 20 in this volume). In Dakar in 
2000, at the World Education Forum that relaunched 
the Education for All program, the role of schools in 
delivering health programs, including deworming, was 
reinvigorated by the launch of the global partnership 
Focusing Resources on Effective School Health (FRESH). 
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Map 13.3 Distribution of Soil-Transmitted Helminth Infection Prevalence for Children Younger than Age 15 Years, 
by Species, 2015
map continues next page
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FRESH was given greater vitality a year later when the 
World Health Assembly endorsed a target of deworming 
75 percent of schoolchildren in member states with 
endemic STH infections. The FRESH principles con-
tinue to guide school health programs and are still being 
used and cited, for example, in the strategic plan for 
national deworming announced in Ethiopia in 2012.
From these beginnings, deworming, especially school-
based deworming, has become a major public health 
program. In the London Declaration on Neglected 
Tropical Diseases announced in 2012, 14 pharmaceutical 
companies committed to donating medicines for 10 of 
the most prevalent NTDs, including STHs. The specific 
donations for STHs are targeted at school-age children 
and comprise 400 million treatments of albendazole 
(GlaxoSmithKline) and 200 million treatments of meb-
endazole (Johnson & Johnson). Medicines donated for 
other purposes, such as ivermectin for onchocerciasis 
and lymphatic filariasis, are also effective against STHs, 
and additional albendazole is donated specifically for 
lymphatic filariasis.
This progress adds up to a substantial volume of 
treatments efficacious against STHs. In 2015, the latest 
date for which treatment data are available for all 
three commonly used anthelmintics, the World Health 
Organization (WHO) reports that approximately 
564 million children (150 million preschool-age chil-
dren and 416 million school-age children) were 
treated with albendazole or mebendazole for STHs 
(WHO 2015a) (table 13.3). While 556.2 million per-
sons (including approximately 36 million preschool- 
age children and 139 million school-age children) 
were treated with albendazole under MDA programs 
targeting elimination of lymphatic filariasis (WHO 
2015b), approximately 113.2 million persons were 
treated with ivermectin under the onchocerciasis 
elimination program in Africa (WHO 2015a). These 
figures suggest that in 2015, more than 1 billion per-
sons were treated with drugs that are efficacious 
against STHs during the course of just one year.
The official estimates of treatment coverage in school-
age children continue to show relatively low, albeit rising, 
levels of coverage, estimated to be about 45 percent in 2014 
(figure 13.1 and table 13.3). These estimates are based on 
the donated drugs provided through WHO mechanisms, 
expressed as a proportion of the world’s school-age 
children. Both the supply (that is, the numerator) and 
the demand (that is, the denominator) continue to rise 
Source: Adapted from Pullan and others 2014 and updated to 2015.
Note: Based on geostatistical models for Sub-Saharan Africa and empirical data for all other regions.
c.  Whipworm
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Map 13.3 Distribution of Soil-Transmitted Helminth Infection Prevalence for Children Younger than Age 15 Years, 
by Species, 2015 (continued)
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leading to little change in coverage year over year reported 
by the WHO. These estimates report the number of doses 
that are donated specifically for school-based deworming 
(about 379 million tablets in 2015); they do not report the 
number of other donated drugs that are efficacious against 
STHs (an additional 900 million doses in 2014) or the 
large number of nongovernmental organization and 
self-administered treatments in the unprogrammed cate-
gory that go unreported. The scale of actual treatment of 
schoolchildren in any year could easily be twice that 
reported in the official statistics.
HEALTH IMPACT OF WORMS AND 
DEWORMING
Although the WHO recommends MDA for vulnerable 
groups, such as children and pregnant women, who live 
in areas with endemic intestinal worm infection, a series 
of reviews from both the Cochrane Collaboration (most 
recently, Taylor-Robinson and others [2015]) and the 
Campbell Collaboration (Welch and others 2016) argues 
that there is substantial evidence that mass deworming 
does not produce health benefits and does not support 
the use of MDA. How can these two views be reconciled?
Substantial Historical Literature on the Clinical 
Consequences of STH Infection
The clinical literature, gathered over the early part of 
the last century, shows significant impacts of intense 
STH infection on health. Through collation of data 
from several different studies that described the occur-
rence of Ascaris-induced intestinal obstruction in spe-
cific regions of endemic countries, and studies on the 
community prevalence of ascariasis in the same regions, 
the incidence of Ascaris-induced intestinal obstruction 
was shown to clearly increase, in a nonlinear fashion, as 
community prevalence of infection increased (de Silva, 
Guyatt, and Bundy 1997a). Similar data collations 
Table 13.3 Total Number of Preschool-Age and School-Age Children Estimated to Require Preventive 
Chemotherapy for Soil-Transmitted Helminths, by WHO Region, 2009 and 2015
WHO region
2009 2015
Requiring PC for 
STHs (millions)
Receiving PC for 
STHs (millions)
Regional 
coverage (%)
Requiring PC for 
STHs (millions)
Receiving PC for 
STHs (millions)
Regional 
coverage (%)
African 283.8 91.0 32 298.0 153.0 51
Americas 45.5 21.1 46 46.9 24.3 52
Eastern 
Mediterranean 78.0 2.5 3 74.4 17.9 24
European 4.3 0.4 9 2.3 0.5 23
South-East Asia 372.0 144.8 39 354.4 172.1 49
Western Pacific 99.1 14.1 14 75.2 32.4 43
Total 882.7 273.9 31 851.2 400.2 47
Source: WHO 2011, 2016.
Note: PC = preventive chemotherapy; STHs = soil-transmitted helminths; WHO = World Health Organization.
Figure 13.1 Reported Global Coverage of Preschool- and School-Age 
Children, 2003–14, with a Projection to the 2020 Target of 75 Percent 
Coverage
Source: Adapted from ﬁ gure 1 of Trusscott, Turner, and Anderson 2015. The data on reported 
coverage are from the World Health Organization, “Neglected Tropical Diseases: PCT Databank,” 
http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/.
Note: Figure shows the treatment coverage of preschool-age and school-age children up to 2014. 
The dashed lines are indicative of the change necessary to reach the goal of 75 percent 
treatment by 2020.
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showed patients with acute intestinal obstruction due 
to ascariasis harbored more than 60 worms in most 
instances, with a 10-fold higher worm burden in fatal 
cases. Children younger than age five years were shown 
to develop obstruction with much smaller worm bur-
dens (de Silva, Guyatt, and Bundy 1997b). A model of 
the global numbers at risk of morbidity and death due 
to ascariasis estimated that in 1990, some 11.5 million 
children were at risk of clinically overt acute illness and 
that some 200,000 children developed serious compli-
cations such as intestinal obstruction, biliary or pan-
creatic disease, appendicitis, and peritonitis, resulting 
in about 10,000 deaths each year (de Silva, Chan, and 
Bundy 1997).
Evidence also points to the effects of Trichuris infec-
tion on growth and development of infected children, in 
particular in those children who have a heavy burden of 
infection. Reports from Jung and Beaver (1951) described 
dysentery, diarrhea, and colitis in children with Trichuris 
infection; heavily infected children more frequently pre-
sented with the more severe symptom of rectal prolapse. 
This heavy infection can lead to a well-described 
Trichuris dysentery syndrome, characterized by dysen-
tery, anemia, growth retardation, finger clubbing, rectal 
prolapse, and a specific trichuriasis colitis (Cooper and 
Bundy 1988). Furthermore, curative treatment for para-
site infection leads to rapid alleviation of these symp-
toms (Cooper and Bundy 1988; Jung and Beaver 1951). 
Studies have recorded significant catch-up growth in 
middle childhood—especially ages four to eight years—
following curative treatment, with significant increases 
in height and weight as well as improvements in cogni-
tion (Callender and others 1998; Cooper and others 
1990; Cooper and others 1995; Nokes and others 1992).
Anemia is associated with trichuriasis colitis and is 
the defining characteristic of hookworm infection. On 
maturation and migration to the gut, hookworms attach 
to the intestinal mucosa and submucosa, rupturing cap-
illaries mechanically as well as through release of anti-
clotting agents to maintain blood flow (Hotez and 
others 2004). The development of anemia is related to 
infection intensity as well as to the duration of infection 
and nutritional status of individuals (Crompton and 
Whitehead 1993; Hall and others 2008). A seminal trial 
by Stoltzfus and others (1997) showed a significant asso-
ciation between hookworm infection and severe ane-
mia, as well as iron deficiency over and above dietary 
intake of iron. The authors predicted that eliminating 
hookworm infections from their study population could 
lead to a reduction in anemia of 25 percent and severe 
anemia by as much as 73 percent.
Thus, the pathology for each of these helminth 
infections can be severe in both immediate effects and 
medium-term consequences for growth and develop-
ment. Furthermore, for each of these infections, cura-
tive treatment leads to alleviation of the immediate 
symptoms as well as to accelerated gains in growth 
and development, indicating that the pathology of 
worm infection can largely be reversed if treated in a 
timely manner.
This literature, now largely historical, on clinical trials 
of patients with known and intense infection compared 
with untreated controls, offers convincing evidence on 
both the effect of infection on patients and the benefits 
of treatment. Such trials should no longer be conducted 
because it would be unethical to withhold treatment 
from patients known to be infected.
Impact of Current MDA-Based Trial Design
The majority of deworming trials today are designed 
quite differently from traditional clinical trials. They are 
based on the operational design of deworming pro-
grams, in which MDA covers all of the target popula-
tion, usually an age class, living in an area where 
infection is endemic, with no measure of individual 
infection status or intensity. Because infection intensity 
is overdispersed, such that most people have lower- 
than-average infection and a minority have intense 
infection (figure 13.2), there will be considerable and 
unknown variance in the intensity of individual infec-
tion. Because the intensity is unknown in any individual, 
so too is the likelihood of morbidity and the potential 
scale of benefit from treatment. With the current trial 
design, the population outcome can only be measured as 
some average of individual benefits. Even were there to 
be considerable benefit for the minority of intensely 
infected individuals, if there is little or no benefit for the 
majority with light infections then the average effect will 
be small. The underlying situation across the population 
is unknowable with current MDA-based trial designs.
To illustrate what the analyses show in practice, we 
compare two comprehensive analyses drawing on the 
same small pool of trials available in this area of research. 
In the first analysis, Taylor-Robinson and others (2015) 
examined both randomized trials of universal deworming 
programs, which include children both with and without 
worms, and studies among groups of infected children 
already screened and diagnosed. They then conducted 
formal meta-analysis for eight outcomes: weight, 
height, middle-upper-arm circumference, triceps skinfold 
thickness, subscapular skinfold thickness, body mass 
index, hemoglobin, and school attendance. They con-
cluded that, while targeted deworming of infected chil-
dren may increase weight gain, for mass deworming 
programs that cover children with and without worms, 
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“There is now substantial evidence that [mass treatment 
of all children in endemic areas] does not improve average 
[emphasis added] nutritional status, hemoglobin, cogni-
tion, school performance, or survival” Taylor-Robinson 
and others (2015, 2). They included a maximum of 11 
estimates from 10 trials for weight gain, with many fewer 
trials for most of the other outcome measures.
In the other analysis, Croke and others (2016) aug-
mented Taylor-Robinson and others’ (2015) sample 
with information from published studies as well as 
several excluded studies and then conducted meta- 
analysis on this augmented sample. Focusing on weight 
gain, for which the number of available studies is 
greatest, they noted that the appropriate test for the 
Figure 13.2 Distribution of Worm Burden
Sources: Panel a, adapted from Hollingsworth, Truscott, and Anderson 2013; panel b, adapted from Truscott and others 2014; panel c, adapted from Truscott, Turner, and Anderson 2015.
Note: epg = eggs per gram of stool. Worm burden indicates the expected number of worms harbored by an individual.
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hypothesis of no treatment effect in all cases is a 
fixed-effect meta-analysis. Using this model, the 
hypothesis of zero weight gain from deworming was 
rejected at the 10 percent level using the original data 
from the Taylor-Robinson and others (2015) study. 
Using the augmented sample, they found a 0.111 kilo-
gram weight gain (p < 0.001) from deworming in a 
fixed-effects model and a 0.134 kilogram weight gain 
(p = 0.01) in a random-effects model.
Noting that including trials from settings with mini-
mal STH prevalence and mass deworming is not recom-
mended because such a policy may minimize the 
estimated impact of deworming, they then estimated 
positive and statistically significant impacts in settings in 
which the WHO recommends multiple doses of mass 
treatment annually (greater than 50 percent prevalence), 
and in settings where the WHO recommends mass 
deworming at least once per year (greater than 20 percent 
prevalence). For high- and medium-prevalence areas 
(greater than 50 percent prevalence of any single STH 
species), the fixed-effects estimate was 0.157 kilogram, 
while the random-effects estimate was 0.182 kilogram. 
For trials in settings with greater than 20 percent preva-
lence, the fixed-effects estimate was 0.142 kilogram, while 
the random-effects estimate was 0.148 kilogram.
Accordingly, while Taylor-Robinson and others 
(2015) highlighted an apparent contradiction between 
the evidence on treatment of infected individuals (evi-
dence of benefit) and mass treatment (no evidence of 
benefit), Croke and others (2016) demonstrated that 
mass deworming also has evidence of benefit, albeit of 
smaller magnitude than the effects identified in targeted 
studies. Evidence for this benefit is particularly strong in 
high- and medium-prevalence settings. The estimated 
weight gain in these universal treatment studies is nota-
bly smaller than in studies of individuals known to be 
infected—on the order of 0.13 and 0.75 kilogram, 
respectively—which would be the logical consequence 
of averaging across a population with an overdispersed 
distribution of intensity of infection and probability of 
morbidity.
The similar results but very different conclusions of 
these two analyses of the same trial datasets may be 
helpful for understanding the paradoxical literature in 
the deworming area. Both analyses found effects with 
targeted treatment trials, as is well documented in the 
clinical literature. Both analyses found small effects on 
weight gain (the measure for which most trials are 
available for meta-analysis) when exploring the effects 
across whole populations with unknown distribution 
of infection intensity—finding these effects significant 
in one analysis and not significant in the other. Resolving 
this debate requires exploring the distribution of 
individual morbidity and infection intensity. One 
important point is that the targeted treatment trials are 
also the earlier trials: detecting average effects in popu-
lations will only become more difficult as infection 
levels continue to decline.
OPTIMIZING PROGRAM DESIGN BY 
MODELING POPULATION DYNAMICS
Both chapters on deworming in the earlier editions of 
Disease Control Priorities emphasized the importance 
of understanding population dynamics as a determinant 
of good program design (Hotez and others 2006; Warren 
and others 1993). This section explores how the popula-
tion dynamics modeling is being used to optimize pro-
gram design and, in particular, what the modeling says 
about the value of MDA versus screen and treat and of 
school-based deworming versus universal coverage.
A common epidemiological feature of STH infec-
tions is the overdispersed distribution of worms 
(figure 13.2, panel a): while many people have a 
medium to low burden of infection, a minority of 
people have a high burden of infection. Because of the 
linear relationship between infection intensity and 
morbidity, individuals with high burdens are most 
likely to suffer health impacts of STHs, to contribute 
the largest number of infectious eggs, and to be rein-
fected following mass treatment, raising the possibility 
that targeting these individuals would be the most 
effective way to control both the health impact and the 
transmission of STHs. However, this approach has 
some practical challenges.
• First, commonly used diagnostics—wet smear in 
saline or Kato-Katz examination of stool samples to 
count eggs—are poor diagnostics of the underlying 
worm burden because of both variations in egg out-
put and the nonlinear relationship to worm burden 
(Anderson and Schad 1985).
• Second, selective diagnosis and treatment involves 
expensive fieldwork, including collecting and ana-
lyzing stool samples and finding, reidentifying, and 
treating highly infected individuals (see next section 
on costs).
• Third, the nature of the overdispersed distribution 
means that a large proportion of the population 
has to be sampled to detect the few who have to be 
treated.
The few field studies that have been performed have 
found that selective treatment of persons with high par-
asite burden is less effective than mass treatment at 
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reducing population-level prevalence (Asaolu, Holland, 
and Crompton 1991); that mass treatment is more 
cost-effective than selective treatment (Holland and oth-
ers 1996); and that school-based deworming is a highly 
cost-effective way to reduce anemia (Brooker and others 
2008; Guyatt and others 2001) in particular settings, 
reflecting the results of modeling studies (Guyatt, Bundy, 
and Evans 1993) and a recent review of costs and cost- 
effectiveness (Turner and others 2015). Current evidence 
suggests that the most cost-effective way to reduce 
high-burden infections in children is through school-
based deworming rather than selective treatment.
Epidemiological studies have also found indirect 
benefits to mass treatment of children, such as reduc-
tions in prevalence of infection in untreated adults 
(Asaolu, Holland, and Crompton 1991; Bundy and 
others 1990). These indirect effects have been found for 
roundworm and whipworm, but different effects were 
found in different settings, reflecting local differences 
in prevalence and distribution of infection. The 
population- level impact of a school-based deworming 
program and the impact on transmission to other 
members of the community and reinfection after treat-
ment depend on the epidemiology of the parasite, effi-
cacy of the treatments, age distribution of the 
population, and coverage of the treatment program. 
For roundworm and whipworm, the highest burden of 
infection is usually in children (figure 13.2, panel b); 
therefore, a school-based program covering preschool- 
and school-age children could have a large impact on 
transmission, particularly in settings with a high pro-
portion of school-age population, provided the treat-
ment used is effective for whipworm (Chan and others 
1994; Turner and others 2016) and prevalence is at 
moderate to low levels. For hookworm, the burden of 
infection tends to be higher in adults; therefore, a 
school-based deworming program is likely to be less 
effective at reducing both morbidity (Coffeng and oth-
ers 2015; Truscott, Turner, and Anderson 2015) and 
transmission at the population level (Anderson, 
Truscott, and Hollingsworth 2014; Anderson and oth-
ers 2013; Anderson and others 2015; Chan and others 
1994). However, systematically excluding a portion of 
the community from treatment can undermine elimi-
nation programs (Coffeng and others 2015), although 
it also helps slow the emergence of drug resistance.
Many of these results are from mathematical model-
ing studies, which have become more complex in recent 
years. An important development has been the valida-
tion of models against repeat time-point data  (figure 13.2, 
panel c); these models are being expanded to include 
the most recent data (Coffeng and others 2015; Truscott, 
Turner, and Anderson 2015). Given that coverage of 
adults is likely to be required to break transmission, anal-
yses have shown that in many settings the higher cost of 
coverage is offset by the lower number of rounds 
required, given that treatment can be stopped when 
transmission has been permanently interrupted (Lo 
and others 2015; Turner and others 2015; Turner and 
others 2016).
This section considers two issues: how treatment can 
bring down intensity and morbidity, and how treatment 
might break transmission. Empirical evidence is avail-
able for the former, but caution should remain about 
the latter. Although MDA has proven to be effective 
with onchocerciasis and lymphatic filariasis, these dis-
eases have much slower epidemic growth rates than do 
STHs, and both require vectors for transmission rather 
than fecal contamination of the environment with 
infective stages.
ESTIMATED COST OF MDA
One of the main arguments for deworming, and the 
basis of the WHO recommendation for the use of MDA, 
especially school-based deworming, is the cost- effectiveness 
arising from an exceptionally low-cost intervention 
delivered infrequently without the need for costly screen-
ing. The value for money of this approach for low- 
income countries has recently been greatly enhanced by 
the availability of donated treatments. This section 
explores the costs in more detail.
MDA offers notable economies of scale (Brooker and 
others 2008; Evans and others 2011) because the cost 
per treatment decreases as the number treated rises 
 (figure 13.3, panel a). This effect occurs because some of 
the most significant costs associated with MDA delivery 
are fixed and do not depend on the number treated: 
increasing the number treated therefore reduces the 
average fixed cost per treatment (Turner and others 
2016). These economies of scale may account for 
much of the observed variation in the costs of delivering 
NTD treatment (Turner and others 2015).
Table 13.4 lists the costs of STHs delivered through 
a variety of MDA program designs. Integrating STH 
programs with other NTD programs or indeed other 
control programs, such as child health days, can pro-
duce economies of scope, by which the average cost 
per treatment declines as a result of delivering two or 
more interventions at once (figure 13.3, panel b); for 
example, integrating NTD programs reduces the over-
all cost between 16 percent and 40 percent (Evans and 
others 2011; Leslie and others 2013). Furthermore, the 
incremental cost of adding deworming into estab-
lished immunization campaigns or child health days 
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Sources: Panel a, data from Brooker and others 2008; panel b, data from Evans and others 2011.
Note: Triple drug administration refers to the co-administration of albendazole, ivermectin, and praziquantel on a single delivery platform in communities where multiple neglected tropical 
diseases are prevalent.
Figure 13.3 Observed Economies of Scale and Scope Associated with Preventive Chemotherapy
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Table 13.4 Key Preventive Chemotherapy Costing Studies Using Albendazole and Mebendazole
Study Country
Target of 
intervention
Primary distribution 
method Results
Brooker and others 
2008
Uganda STHs and SCH School based 
(annually)
The overall economic cost per child treated in the six districts was 
US$0.54, which ranged from US$0.41 to US$0.91 (delivery costs: 
US$0.19–US$0.69). The overall financial cost per child treated was 
US$0.39. Costs are in 2005 US$. 
Goldman and 
others 2007
Multicountry 
study
LF (and STHs 
indirectly)
Community based 
(annually)
The financial cost per treatment ranged from US$0.06 to US$2.23. 
Costs are in 2000–03 US$ (base year 2002). 
Evans and others 
2011
Nigeria STHs, SCH, 
LF, and 
onchocerciasis
Community based 
(annually)
In 2008, school-age children in eight local government areas received 
a single round of ivermectin and albendazole followed at least one 
week later by praziquantel. The following year, a single round of triple 
drug administration was given, reducing the programmatic costs 
for MDA, not including drug and overhead costs, 41 percent (from 
US$0.078 to US$0.046 per treatment). Costs are in 2008–09 US$.
Goldman and 
others 2011
Haiti STHs and LF School based and 
community based 
(annually)
The cost per treatment was US$0.64, including the value of donated 
drugs. The program cost, excluding the value of the donated drugs, 
was US$0.42 per person treated. Costs are in 2008–09 US$.
Leslie and others 
2011
Niger STHs and SCH School based and 
community based 
(annually)
The full economic cost of delivering the school-based and 
community-based treatment was US$0.76 and US$0.46, 
respectively. Including program costs alone, the values were 
US$0.47 and US$0.41, respectively. Costs are in 2005 US$. 
Leslie and others 
2013
Niger STHs, SCH, LF, 
and trachoma
School based and 
community based 
(annually)
The average economic cost of integrated preventive chemotherapy 
was US$0.19 per treatment, excluding drug costs. The average 
financial cost per treatment of the vertical SCH and STH control 
program (before the NTD programs were integrated) was US$0.10. 
Costs in are 2009 US$.
table continues next page
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with an already developed delivery infrastructure is 
very small—approximately US$0.03 per treatment 
(Boselli and others 2011)—and much lower than 
delivering treatment through vertical national 
deworming programs (Turner and others 2015); how-
ever, it may target younger children only and not 
access the age group with intense infection. This pos-
sibility highlights the critical need to consider the local 
context of NTD control programs when comparing 
the reported costs of MDA.
CONCLUSIONS
STH deworming programs are among the largest pub-
lic health programs in low- and lower-middle-income 
countries as measured by coverage. The actual scale of 
these programs is unknown but is substantial; more 
than 1 billion donated doses of medicines effective 
against STHs are delivered by formal programs and 
supplemented by widespread self-treatment and 
unprogrammed activities. Deworming is one of the 
most common self-administered treatments in low- 
income countries; there is no question that there is 
strong community demand for this intervention. The 
large majority of formal MDA programs for STHs is 
school based.
STH infection is declining worldwide, likely reflecting 
the influence of improved hygiene and sanitation associ-
ated with global declines in poverty. The decline also 
reflects control efforts during the twentieth century that 
have largely eliminated STHs as a public health problem 
in previously endemic areas of North America (Mexico 
and the United States), Japan, Korea, and upper- 
 middle-income countries throughout southern and 
eastern Asia.
This trend accelerated during the past decade, espe-
cially in the poorest countries where infection was previ-
ously most intense. Estimates are crude, but suggest that 
infection prevalence in school-age children was halved 
between 2010 and 2015. Efforts are underway to provide 
more extensive and more accurate surveys of infection 
status, supported by the creation of integrated databases 
that provide contemporary estimates of infection and 
treatment coverage. Efforts to monitor the potential 
emergence of drug resistance in treated populations are 
also increasing.
Much of the treatment is delivered through schools 
and targets school-age children. In 2015, India had the 
largest public health intervention ever conducted in a 
single day, deworming 89 million schoolchildren during 
the Annual School Deworming Day. The target for 2016 
is 270 million schoolchildren. Modeling suggests that 
expanding programs to include other age groups might 
break transmission, and studies are exploring the utility 
of this approach in practice. Increasingly, countries are 
combining MDA for lymphatic filariasis and STHs since 
both use the same anthelmintics.
STH infection has been shown to be associated with 
clinical and developmental outcomes that are largely 
reversible by treatment (box 13.1). Both historical and 
contemporary trials of targeted treatment of individuals 
known to be infected have also demonstrated benefit 
from treatment.
Table 13.4 Key Preventive Chemotherapy Costing Studies Using Albendazole and Mebendazole (continued)
Study Country
Target of 
intervention
Primary distribution 
method Results
Boselli and others 
2011
Lao PDR STHs within a 
child health day 
campaign 
Child health days 
(annually)
The incremental cost of adding deworming into the national 
immunization campaign was US$0.03 per treatment (delivery costs: 
US$0.007). The cost per treatment for the vertical school-based 
national deworming campaign (targeting school-age children) was 
US$0.23. Costs are in 2009 US$.
Fiedler and 
Semakula 2014
Uganda STHs within 
a vitamin A 
supplementation 
campaign
Child health days (one 
round)
The average economic cost per child reached by the child health day 
program was US$0.22 (per round). Costs are in 2010 US$.
Note: LF = lymphatic ﬁ lariasis; MDA = mass drug administration; NTD = neglected tropical disease; SCH = schistosomiasis; STHs = soil-transmitted helminths. For a more detailed summary of cost 
data for preventive chemotherapy, see Keating and others (2014) and Turner and others (2015).
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The findings of a small group of more recent clinical 
trials based on MDA have been controversial. These tri-
als measure average change in health metrics for the 
whole population treated, irrespective of the infection 
status of individuals. Since morbidity is related to inten-
sity, and intensity has an overdispersed distribution in 
populations, the average change in health metrics likely 
reflects the outcomes for a majority of people who are 
lightly infected and may derive limited benefit from 
treatment and for a minority who are more intensely 
infected and may derive greater benefit. The actual dis-
tribution of intensity and infection in these trial popula-
tions is unknown because individual screening is not 
necessary for MDA. The controversy arises because the 
change when averaged across the whole population is 
typically small, and there are insufficient data to deter-
mine with confidence whether the small size of the 
change reflects the underlying population distribution 
or the scale of benefit. An additional factor is that these 
more recent trials are conducted against the background 
of successful control efforts and the correspondingly low 
intensity of infection in most of the study populations. 
Studies are now being designed that aim to separate 
these factors.
The controversy in this area has extended from the 
results themselves to their policy implications. There is 
general agreement that STH infection can affect health, 
but disagreement regarding the circumstances that 
would justify an MDA program. While this debate con-
tinues, demand for MDA is continuing in the endemic 
countries and self-treatment is continuing on a massive 
scale. The debate would benefit from quantitative pol-
icy analysis setting out the population parameters that 
would and would not justify an MDA approach (see 
chapter 29 in this volume, Ahuja and others 2017, for 
an example of how this analysis has been approached 
from an economic perspective). The trend toward inte-
grated MDA programs that target both lymphatic filar-
iasis and STHs would also change the policy question 
being asked.
Looking to the future, we can expect infection levels 
to continue to decline as a result of the combination of 
high levels of treatment and continuing economic devel-
opment trends in poor communities. We can also hope 
for a resolution of the worm wars as methods for assess-
ing impact improve to reflect epidemiological realities, 
but this goal may be compromised if levels of impact 
continue to fall with sustained control.
Box 13.1
WHO Recommendations for the Control of Morbidity Attributable to Soil-Transmitted Helminths
Present recommendations
Since 2001, the World Health Organization (WHO) 
has recommended, for the prevention and control 
of the morbidity due soil-transmitted helminth 
(STH) infection, the implementation of preventive 
chemotherapy (PC) in the form of periodical, large- 
scale administration of anthelmintics to population 
groups at risk of morbidity due to infection.
Children and women of childbearing age are consid-
ered the population groups with the highest risk of 
morbidity from STH infection, because they are in a 
period of life in which they are particularly vul-
nerable to nutrient deficiencies associated with 
infection.
The current recommendation is for treatment once a 
year when the prevalence of STH infection is more 
than 20 percent and twice a year when prevalence 
exceeds 50 percent. The PC strategy is being imple-
mented worldwide; in 2015, more than 50 percent of 
preschool children and more than 63 percent of school-
age children in areas endemic for STHs were treated 
with anthelmintics.
Updating the recommendations
A WHO Guideline Review Committee (GRC) com-
prising independent experts met in Geneva in April 
2016 to reassess the WHO recommendations on 
STHs control in light of scientific and programmatic 
evidence cumulated during the last 15 years of PC 
interventions. The conclusions of the GRC are pres-
ently being finalized and are expected to be published 
in early 2017.
Source: WHO 2001. 
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NOTE
World Bank Income Classifications as of July 2014 are as fol-
lows, based on estimates of gross national income (GNI) per 
capita for 2013:
• Low-income countries (LICs) = US$1,045 or less
• Middle-income countries (MICs) are subdivided:
a) lower-middle-income = US$1,046 to US$4,125
b) upper-middle-income (UMICs) = US$4,126 to US$12,745
• High-income countries (HICs) = US$12,746 or more.
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